COVID-19: Global infection tally crosses 101.8 million

30-01-2021 12:45:11
By :
Notice: Trying to get property 'fName' of non-object in /home/newobserverdawn/public_html/module/Application/view/application/index/news.phtml on line 23

Notice: Trying to get property 'lName' of non-object in /home/newobserverdawn/public_html/module/Application/view/application/index/news.phtml on line 23


The global death toll from COVID-19 has crossed 2.198 million, while the infection tally has gone past 101.8 million cases, the US-based Johns Hopkins University informed in its latest update.


The JHU is the foremost and most credible global institution that tracks and compiles data regarding the pandemic.


While the number of COVID-19 cases globally stood at 101,803,875, total fatalities were pegged at 2,198,644.


The United States still has the highest case count in the world, with 25,840,365, including 434,696 fatalities.


In what can be a major point of concern for the US, the US National Institute of Allergy and Infectious Diseases Director Anthony Fauci has warned that the new strain of the novel coronavirus that first appeared in the United Kingdom will become more dominant in the United States by the middle of spring. The UK strain of the virus is even more contagious.


Meanwhile, the international team from the World Health Organization (WHO) which is visiting China for tracing the origins of the virus, has for the first time met with Chinese scientists in Wuhan.


WHO Director-General Tedros Adhanom Ghebreyesus on Friday warned against the COVID-19 vaccine hoarding by some countries, he said that such practices could slow down global recovery from the pandemic and would be an impediment to economic recovery as well


The European Commission has authorized the use of vaccine developed by the UK-Swedish pharmaceutical giant AstraZeneca for use in the European Union.


The company would be delivering 400 million doses of the vaccine in the near future.


US company Novavax has claimed that it's corona vaccine has showed 89.3 percent efficacy during the phase 3 trials conducted in the United Kingdom.



Comments

Note : Your comments will be first reviewed by our moderators and then will be available to public.

Get it on Google Play